(234) conducted CheckMate-498 phase III clinical study comparing nivolumab or TMZ for OS, each in combination with radiotherapy (RT), in patients with newly diagnosed MGMT unmethylated GBM, failed to meet its intended target improvement OS endpoint (ClinicalTrials.gov, NCT02617589). Here, MGMT is linked to glioblastoma.